SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
allatwwk
bobbseytwins2001
chandler27
diaperdaddy
dorightbythem
drtom1234
erippetoe
idahoranch1
JJINV
KeeptheFaith
li3511
patlawche11
rodneyh07
summer_sky
sysiphus
To: KeeptheFaith who wrote (49576)1/22/2019 12:36:36 PM
From: stockdoc7715 Recommendations   of 63322
 
My understanding is that the FDA does a full review of the application and lists any deficiencies in the CRL. As they did not ask for additional clinical data I conclude that they are satisfied on the efficacy of 132. I don't think the FDA would hide the ball or move the goalposts with regards to something this important.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News